The Filing Desk

ANI Pharmaceuticals vs Ionis Pharmaceuticals

ANI Pharmaceuticals ANIP · Ionis Pharmaceuticals IONS · Pharmaceuticals

Ionis Pharmaceuticals reported revenue of $944 million in fiscal 2025, about the same as ANI Pharmaceuticals' $883 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Ionis Pharmaceuticals' grew 33.8%. ANI Pharmaceuticals had an operating margin of 12.6%, against -40.5% at Ionis Pharmaceuticals. Free cash flow was $171 million at ANI Pharmaceuticals and −$320 million at Ionis Pharmaceuticals.

Side by side

ANI PharmaceuticalsIonis Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$883M$944M
Revenue growth43.8%33.8%
Revenue growth a year, last 5 years33.5%5.3%
Gross margin—98.3%
Operating margin12.6%−40.5%
Net margin8.9%−40.4%
Free cash flow$171M−$320M
Free cash flow margin19.4%−33.9%
Return on capital15.9%—
Net debt to EBITDA0.1x—
Dividends and buybacks$13M$0M
Change in diluted share count9.9%7.0%
Last close$69.13$27.22
P/E at the last close13.8×—
Insider trades, last 12 monthssold $13.6 millionbought $1.1 million, sold $117.5 million
Piotroski F-score6 of 83 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ANI PharmaceuticalsIonis Pharmaceuticals
Operating margin
Percent of revenue
ANI PharmaceuticalsIonis Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsIonis Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Ionis Pharmaceuticals pages.